Despite China Weakness, Lilly Gung-Ho On Forteo, Humalog
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly said in its Q4 earning call that slowdown in emerging markets would continue in the coming year, highlighting a tough year in China, with possible worse growth in the country depending on its on-going whole pricing policies. Though some brands will remain strong and accelerate growth, particularly Forteo.